Found 43 hits of Enzyme Inhibition Constant Data
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 2.00E+5nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 3.00E+5nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 5.00E+5nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 6.00E+5nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 8.00E+5nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 9.00E+5nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.20E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 2.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 2.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 2.10E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 2.10E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 2.30E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 2.40E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 2.40E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 2.50E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 3.20E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 3.30E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 3.50E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 3.50E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 3.60E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 3.90E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 4.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 4.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 4.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 4.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 4.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 4.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 4.40E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 4.40E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 4.40E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 5.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 5.00E+6nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.00E+7nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.00E+7nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.00E+7nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.00E+7nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.00E+7nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.00E+7nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.00E+7nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase Src(Homo sapiens (Human))
Aventis Pharma
Curated by ChEMBL
Aventis Pharma
Curated by ChEMBL
Affinity DataIC50: 1.00E+7nMAssay Description:The compound was evaluated for its binding affinity towards phosphotyrosine binding pocket of Src protein tryrosine kinase SH2 domainMore data for this Ligand-Target Pair